BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $220
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan David Seigerman maintains an Outperform rating on AbbVie and raises the price target from $214 to $220.
October 17, 2024 | 1:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has reaffirmed its Outperform rating on AbbVie and increased the price target from $214 to $220, indicating confidence in the company's future performance.
The reaffirmation of an Outperform rating and an increased price target by a reputable analyst suggests a positive outlook for AbbVie's stock, likely leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100